WO2011011905A1 - 一种降血脂、降血糖复方制剂的制备工艺 - Google Patents

一种降血脂、降血糖复方制剂的制备工艺 Download PDF

Info

Publication number
WO2011011905A1
WO2011011905A1 PCT/CN2009/001065 CN2009001065W WO2011011905A1 WO 2011011905 A1 WO2011011905 A1 WO 2011011905A1 CN 2009001065 W CN2009001065 W CN 2009001065W WO 2011011905 A1 WO2011011905 A1 WO 2011011905A1
Authority
WO
WIPO (PCT)
Prior art keywords
hours
ethanol
parts
supernatant
ginseng
Prior art date
Application number
PCT/CN2009/001065
Other languages
English (en)
French (fr)
Inventor
王茂祥
Original Assignee
Wang Maoxiang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wang Maoxiang filed Critical Wang Maoxiang
Publication of WO2011011905A1 publication Critical patent/WO2011011905A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4875Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284Atractylodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/42Cucurbitaceae (Cucumber family)
    • A61K36/424Gynostemma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734Crataegus (hawthorn)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/884Alismataceae (Water-plantain family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the invention provides a preparation process for reducing blood lipid and blood sugar lowering compound preparation, and belongs to the field of traditional Chinese medicine pharmaceutical technology. Background technique
  • the “hypolipidemic and hypoglycemic compound preparation” relates to a compound consisting of 10-20 parts of Atractylodes, 10-20 parts of Hawthorn, 5-10 parts of Alisma, 1-5 parts of ginseng, and 0.25-2 parts of Gynostemma pentaphyllum.
  • the preparation, the existing preparation method of the composite preparation process parameters are not scientific enough, the raw material active ingredients can not be extracted to the maximum extent, and therefore, the use effect is also affected. Summary of the invention
  • the invention discloses a preparation process for reducing blood lipid and blood sugar lowering compound preparation, which has the characteristics of reasonable process parameters, small loss of active ingredient of raw materials and high bioavailability.
  • the preparation process of the present invention is as follows:
  • step 4 Take the refined extract of step 3, add the ginseng powder of step 1 and 0.25-2 parts of Gynostemma pentaphyllum powder, mix, dry and pulverize under 60 °C, and pass through 40-200 mesh sieve to obtain fine powder. Add 10%-30% of the fine powder weight of 0%-95% ethanol, mix and disinfect, make soft material, pass the 12-18 mesh sieve granules, dry at 60 ° C for 2-3 hours, capsule .
  • Efficacy ingredient content Total saponin (based on ginsenoside Re) per 100g capsule content 4. 5g, Total flavonoids (in terms of rutin) 131. 5mg
  • Dosage 3 times / day; 0. 8 ⁇ 1. 2 g / time.
  • the positive effects of the invention are as follows: The preparation steps are scientific, the process parameters are reasonable, the loss of active ingredients of the raw materials is small, the yield is high, the quality is stable, and the cost is low.
  • Atractylodes Rhizome, Hawthorn, Alisma, and Ginseng were purchased from Bizhou Xinxiang Pharmaceutical Co., Ltd., and the indicators met the "People's Republic of China Pharmacopoeia (2005 Edition)"standard; Gynostemma saponins were purchased from Xi'an Hongsheng Biological Technology Co., Ltd., in line with the Ministry of Health of the People's Republic of China standard WS 3 - Z-006- 93 (Z).
  • Atractylodes 20kg, Hawthorn 10kg, Alisma 10kg water and cold soak for 2 hours, decocted 3 times, each time 1 hour, decoction filtered, combined filtrate, concentrated under reduced pressure to a relative density of 1-1.30 (Beauty, 30-8CTC ), release, get concentrated liquid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

一种降血脂、 降血糖复方制剂的制备工艺 技术领域
本发明提供一种降低血脂、 降血糖复方制剂的制备工艺, 属于中医制药技 术领域。 背景技术
本发明涉及的 "降血脂、 降血糖复方制剂"是由苍术 10-20份、 山楂 10-20 份、 泽泻 5-10份、 人参 1-5份、 绞股蓝总甙 0.25-2份组成的复方制剂, 该复合 制剂现有的制备方法工艺参数还不够科学, 原料有效成分不能得到最大限度的 提取, 因此, 也影响了其使用效果。 发明内容
本发明公开一种降低血脂、 降血糖复方制剂的制备工艺, 具有工艺参数合 理, 原料有效成分损失小, 生物利用度高的特点。
本发明的制备工艺如下:
1、 取人参 1-5份, 捡去杂质, 洗净, 80-200Ό灭菌 5-60min, 干燥, 粉碎, 过 40-200目筛, 得人参粉, 备用;
2、 苍术 10-20份、 山楂 10-20份、 泽泻 5-10份加水冷浸 0.5-2小时, 煎煮 2〜4次, 每次 0.5〜2小时, 煎液滤过, 合并滤液, 减压浓缩至相对密度为 1-1.30
(波美计, 30-80°C ) , 放出, 得浓缩液;
3、 在步骤 2的浓缩液中加乙醇到含醇量 10%-95%, 静置 12小时, 取上清 液, 沉淀用 10%-95%乙醇洗二次, 溶液并入上清液, 上清液减压回收乙醇, 得 精制浸膏;
4、 取步骤 3的精制浸膏, 加入步骤 1的人参粉和 0.25-2份绞股蓝总甙粉, 混合, 在 60°C以下减压干燥、 粉碎, 过 40-200目筛, 得细粉, 加入其 10%-30% 细粉重量的 0%-95%浓度的乙醇,混匀消毒,制软材,过 12-18目筛制粒,在 60°C 以下干燥 2-3小时, 装胶囊。
功效成分含量: 每 100g胶囊内容物中含总皂甙(以人参皂甙 Re计) 4. 5g, 总黄酮 (以芦丁计) 131. 5mg
用法用量: 3次 /日; 0. 8〜1. 2g/次。
本发明的积极效果在于: 制备步骤科学, 工艺参数合理, 原料有效成分损失 小, 产量高、 质量稳定、 成本低。
本发明实施例中的苍术、 山楂、 泽泻、 人参购自毫州市信想药业有限公司, 各项指标符合 《中华人民共和国药典 (2005年版) 》 标准; 绞股蓝皂甙购自西 安鸿生生物技术有限公司,符合中华人民共和国卫生部部标准 WS3- Z-006- 93( Z)。
具体实施方式
通过以下实施例进一步举例描述本发明, 并不以任何方式限制本发明, 在 不背离本发明的技术解决方案的前提下, 对本发明所作的本领域普通技术人员 容易实现的任何改动或改变都将落入本发明的权利要求范围之内。
实施例 1
1、 取人参 30kg, 捡去杂质, 洗净, 置卧式灭菌柜中 200Ό灭菌 60min, 取 出, 干燥, 粉碎, 过 40-200目筛, 得人参粉, 备用。
2、 苍术 160kg、 山楂 160kg、 泽泻 75kg加水冷浸 0.5-2小时, 煎煮 2次, 每次 1小时,煎液滤过,合并滤液,减压浓缩至相对密度为 1-1.30 (波美计, 30-80 °C ) , 放出, 得浓缩液。
3、 在相对密度为 1-1.30 (波美计, 30-80Ό ) 的浓缩液中加乙醇至含醇量 75%, 静置 12小时, 取上清液, 沉淀用 85%乙醇洗二次, 溶液并入上清液, 上 清液减压回收乙醇, 得精制浸膏。
4、取精制浸膏,加入步骤 1的人参粉和 11kg绞股蓝总甙粉,混合,在 60 °C 以下减压干燥、 粉碎, 过 40-200目筛, 得细粉, 加入 30%细粉重量的 65%浓度 的乙醇, 混匀消毒, 制软材, 过 12-18目筛制粒, 在 60Ό以下干燥 2-3小时, 装胶囊。 每 100g胶囊内容物中含总皂甙(以人参皂甙 Re计) 4. 5g,总黄酮 (以 芦丁计) 142. 5mg。
实施例 2
1、 取人参 lkg, 捡去杂质, 洗净, 置卧式灭菌柜中 180°C, 灭菌 10min, 取 出, 干燥, 粉碎, 过 40-200目筛, 得人参粉, 备用。
2、 苍术 10kg、 山楂 15kg、 泽泻 5kg加水冷浸 0.5-2小时, 煎煮 4次, 每次 1小时, 煎液滤过, 合并滤液, 减压浓缩至相对密度为 1-1.30 (波美计, 30-80 °C ) , 放出, 得浓縮液。
3、 在相对密度为 1-1.30 (波美计, 30-80°C ) 的浓缩液中加乙醇至含醇量 50%, 静置 12小时, 取上清液, 沉淀用 75%乙醇洗二次, 溶液并入上清液, 上 清液减压回收乙醇, '得精制浸膏。
4、 取精制浸膏, 加入人参粉、 1kg绞股蓝总甙粉, 混合, 在 60Ό以下减压 干燥、 粉碎, 过 40-200目筛, 得细粉, 加入 20%细粉重量的 95%浓度的乙醇, 混匀消毒, 制软材, 过 12-18目筛制粒, 在 60°C以下干燥 2-3小时, 装胶囊。 每 100g胶囊内容物中含总皂甙 (以人参皂甙 Re计) 4. 9g,总黄酮 (以芦丁计) 139. 5mg。
实施例 3
1、 取人参 5kg, 捡去杂质, 洗净, 置卧式灭菌柜中 200°C, 灭菌 60min, 取 出, 干燥, 粉碎, 过 40-200目筛, 得人参粉, 备用。
2、 苍术 20kg、 山楂 10kg、 泽泻 10kg加水冷浸 2小时, 煎煮 3次, 每次 1 小时,煎液滤过,合并滤液,减压浓缩至相对密度为 1-1.30 (波美计, 30-8CTC ), 放出, 得浓缩液。
3、 在相对密度为 1-1.30 (波美计, 30-80Ό ) 的浓缩液中加乙醇至含醇量 85%, 静置 12小时, 取上清液, 沉淀用 75%乙醇洗二次, 溶液并入上清液, 上 清液减压回收乙醇, 得精制浸膏。
4、 取精制浸膏, 加入人参粉、 2kg绞股蓝总甙粉, 混合, 在 60°C以下减压 干燥、 粉碎, 过 40-200目筛, 得细粉, 加入 15%细粉重量的水, 混匀消毒, 制 软材, 过 12-18目筛制粒, 在 60°C以下干燥 2-3小时, 装胶囊。 每 100g胶囊内 容物中含总皂甙 (以人参皂甙 Re计) 4.5g,总黄酮 (以芦丁计) 131.5mg。

Claims

权利要求
1、 一种降血脂、 降血糖复方制剂的制备工艺, 其特征在于包括以下步骤:
1)取人参 1-5份, 于 80-200。C灭菌 5-60分钟, 干燥, 粉碎, 过 40-200曰 筛;
2) 苍术 10-20份、 山植 10-20份、 泽泻 5-10份加水冷浸 0.5-2小时, 煎煮 2~4次, 每次 0.5~2小时, 煎液滤过, 合并滤液, 减压浓缩至相对密度为 1-1.30 (波美计, 30-80。C), 得浓缩液;
3) 在步骤 2 的浓縮液中加乙醇到含醇量 10%-95°/。, 静置 12小时, 取上清 液, 将沉淀用 10%-95% 乙醇洗二次, 溶液并入上清液, 将上清液减压蒸馏, 得 精制浸膏;
4) 取步骤 3的精制浸膏, 加入步骤 1 的人参粉和 0.25-2份绞股蓝总甙粉, 混合,在 60°C以下减压干燥、粉碎, 过 40-200目筛, 得细粉, 加入其 10%-30% 细粉重量的 0%-95%浓度的乙醇, 混勾过 12-18 目筛制粒, 在 60°C 以下干燥 2-3 小时, 装胶囊。
PCT/CN2009/001065 2008-09-26 2009-09-22 一种降血脂、降血糖复方制剂的制备工艺 WO2011011905A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200810051221.8 2008-09-26
CN200810051221A CN101366884B (zh) 2008-09-26 2008-09-26 一种降血脂、降血糖复方制剂的制备工艺

Publications (1)

Publication Number Publication Date
WO2011011905A1 true WO2011011905A1 (zh) 2011-02-03

Family

ID=40410976

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2009/001065 WO2011011905A1 (zh) 2008-09-26 2009-09-22 一种降血脂、降血糖复方制剂的制备工艺

Country Status (2)

Country Link
CN (1) CN101366884B (zh)
WO (1) WO2011011905A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526264A (zh) * 2012-01-04 2012-07-04 山东省中医药研究院 一种具有降血脂功效的中药制剂及其制备方法
CN102600228A (zh) * 2012-04-10 2012-07-25 湖南麓山天然植物制药有限公司 一种绞股蓝总苷颗粒中绞股蓝总苷的制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101366882B (zh) * 2008-09-26 2010-04-21 茂祥集团吉林制药有限公司 一种具有降低血脂血糖功能的复方制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1961699A (zh) * 2006-11-24 2007-05-16 朱迅 一种降脂健身茶及其制作方法
CN101366882A (zh) * 2008-09-26 2009-02-18 茂祥集团吉林制药有限公司 一种具有降低血脂血糖功能的复方制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1255149C (zh) * 2004-08-09 2006-05-10 广东庆发药业有限公司 一种药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1961699A (zh) * 2006-11-24 2007-05-16 朱迅 一种降脂健身茶及其制作方法
CN101366882A (zh) * 2008-09-26 2009-02-18 茂祥集团吉林制药有限公司 一种具有降低血脂血糖功能的复方制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WANG,SHIBIAO: "Clinical observation of compound Gynostemma Pentaphyllum tea in treating hyperlipidemia", XINJIANG JOURNAL OF TRADITIONAL CHINESE MEDICINE, no. 3, 1995, pages 28 - 29 *
WANG,YIPING ET AL.: "Observation of Efficacy on 60 Cases of Hyperlipidemia Treated with Jiang Zhi Chong Ji", JOURNAL OF ANHUI TRADITIONAL CHINESE MEDICAL COLLEGE, no. 1, 1996, pages 23 - 25 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526264A (zh) * 2012-01-04 2012-07-04 山东省中医药研究院 一种具有降血脂功效的中药制剂及其制备方法
CN102600228A (zh) * 2012-04-10 2012-07-25 湖南麓山天然植物制药有限公司 一种绞股蓝总苷颗粒中绞股蓝总苷的制备方法

Also Published As

Publication number Publication date
CN101366884A (zh) 2009-02-18
CN101366884B (zh) 2010-05-12

Similar Documents

Publication Publication Date Title
CN104771563B (zh) 一种补肾的中药复方制剂及制备方法
CN105031294A (zh) 铁皮石斛多糖青钱柳含片及其制备方法
CN102119964B (zh) 一种预防和治疗冠心病心绞痛的提取物,它们的制备方法及用途
CN104068391B (zh) 一种罗汉果甙ⅳ含量高的芦荟罗汉果复方胶囊
CN102961414A (zh) 中草药原浆及其应用
CN104982597B (zh) 一种多功能复合速溶茶及其制备方法和用途
WO2011011905A1 (zh) 一种降血脂、降血糖复方制剂的制备工艺
WO2010034134A1 (zh) 中药浓缩丸的制备方法
CN102302609A (zh) 一种改善亚健康的复方中药制剂
CN104001004A (zh) 一种治疗骨折和骨质疏松的中药组合物及其制备方法和应用
CN106362004A (zh) 一种复方鲜石斛颗粒及其制备方法
CN105943576A (zh) 一种刺五加的提取方法及刺五加保健品
CN102526665B (zh) 一种清热退烧、治疗感冒的中药颗粒剂
CN101869675B (zh) 一种治疗暑湿感冒的中药组合物颗粒剂及其制备方法
CN103610822A (zh) 一种治疗结节性脂膜炎的中药
CN103961441A (zh) 一种中药复方制剂及其制备方法和药盒
CN102772660A (zh) 新型同时降血脂和降血糖的中药组合物及其制法
CN106138226A (zh) 一种防治猪高热病的中药颗粒剂及其制备方法
CN109078115B (zh) 一种用于消化道出血的中药制剂及其制备方法
CN112641826A (zh) 一种紫苏籽提取物及其制备方法、应用
CN105616468A (zh) 一种刺五加的提取方法及刺五加保健品
CN100363025C (zh) 附子颗粒的制备方法
CN104068408A (zh) 一种罗汉果甙ⅳ含量高的芦荟罗汉果复方胶囊
CN104547285B (zh) 一种含有沉香叶的、安神助睡眠的组合物
CN102406673A (zh) 预防治疗呼吸道、泌尿系统感染的土牛膝酮苷药物及其制剂、制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09847691

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09847691

Country of ref document: EP

Kind code of ref document: A1